| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Intermune Pharmaceuticals, Inc. |
| 3294 West Bayshore Road, Palo Alto, CA 94303 * (650) 493-8333 |
| Business Description | The company develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. |
| Offering Information Company has | |||
| Trading As | ITMN (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 2/3/00 |
| Domestic Shares Offered | 6,250,000 | Offer Date | 3/23/00 |
| Foreign Shares Offered | 0 | Filing Range | $17.00 - $19.00 |
| Company Shares | 6,250,000 | Offer Price | $20.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.400 |
| Gross Proceeds | $125,000,000 | Selling | $0.840 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | - - | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Warburg Dillon Read LLC | Lead Manager | (203) 719-3000 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| Prudential Volpe Technology | Co-manager | (415) 274-4463 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/98 | 12/31/99 | |||||
| Revenues | - | - | - | - | 0.556 | - | - |
| Income from Oper. | - | - | - | -6.127 | -6.264 | - | - |
| Net Income | - | - | - | -6.072 | -6.210 | - | - |
| E.P.S | - | - | - | - | -8.940 | - | - |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -4.37 | - | - | ||||
| Cash Flow - Inv. | -0.47 | - | - | ||||
| Cash Flow - Fin. | - | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 5.86 | Current Assets | 5.58 | Current Ratio | 1.28 |
| Total Liab. | 13.75 | Current Liab. | 4.35 | Debt Ratio | 234.89% |
| Total Equity | -7.90 | Working Cap. | 1.22 | Debt to Equity Ratio | - |
| Cash | 3.77 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for clinical development and commercialization of our existing products, in-licensing new products, working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Entities affiliated with Warburg, Pincus Equity Partners, L.P. | 21.51 | |
| Entities affiliated with Sanderling Ventures | 21.51 | |
| Entities affiliated with BioAsia Investments, LLC | 11.13 | |
| Entities affiliated with Sofinnova Ventures | 8.98 | |
| Genetech, Inc. | 6.84 | |
| Connectics Corporation | 6.81 | |
| Veron International Ltd. | 5.63 | |
| Note: represents ownership of 5% or more prior to the offering. | ||